Nanozymes based on functionalized iridium oxide-modified gold nanoparticles for combination therapy

RSC Advances 2026 Open access

Read full text
Authors: Yanfang Hu, Kaizheng Jia, Zhijie Guo, Yige Guo, Wenshuo Hou, Xiaofei Chen, Abdukader Abdukayum
DOI: 10.1039/d5ra07054f
Cited by: 1
References: 37

Abstract

, the survival rates of HeLa and HepG2 cells were 35.6% and 46.8%, respectively. In conclusion, PIrS@Au shows potential application in tumour combination therapy.

Fields of Study & Subjects

Advanced Nanomaterials in Catalysis Nanoplatforms for cancer theranostics Nanocluster Synthesis and Applications

Publication details

Journal / source
RSC Advances
Publisher
Royal Society of Chemistry (RSC)
Volume
16
Issue
11
Pages
9659–9665
Publication date
1 January 2026
Language
EN